Stockscreener 앱 받기
2.24
2.18%
-0.05
시간 외 거래:
2.25
0.010
+0.45%
전일 마감가:
$2.29
열려 있는:
$2.26
하루 거래량:
8.82M
Relative Volume:
1.31
시가총액:
$734.49M
수익:
$4.41M
순이익/손실:
$-67.85M
주가수익비율:
-9.9203
EPS:
-0.2258
순현금흐름:
$-57.15M
1주 성능:
-4.27%
1개월 성능:
+40.88%
6개월 성능:
+67.16%
1년 성능:
+308.09%
1일 변동 폭
$2.14
$2.30
1주일 범위
$2.14
$2.725
52주 변동 폭
$0.5314
$2.725
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
2.24 | 750.88M | 4.41M | -67.85M | -57.15M | -0.2258 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Canaccord Genuity | Buy |
| 2026-03-11 | 개시 | Oppenheimer | Outperform |
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen, Inc. pushes innovation in modifier gene therapies to address blindness - Traders Union
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen (OCGN) Receives Buy Rating from Canaccord Genuity - GuruFocus
Ocugen a new buy at Canaccord on pipeline for retinal diseases (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports 2025 results and clinical progress across gene therapy pipeline - MSN
Ocugen Q4 2025 earnings preview - MSN
Canaccord Genuity initiates coverage of Ocugen (OCGN) with buy recommendation - MSN
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data - MSN
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
Ocugen, Inc. (NASDAQ:OCGN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
OCGN Coverage Initiated by Canaccord Genuity with 'Buy' Rating a - GuruFocus
Canaccord Genuity Group Begins Coverage on Ocugen (NASDAQ:OCGN) - MarketBeat
Ocugen (NASDAQ:OCGN) Sets New 1-Year HighWhat's Next? - MarketBeat
Ocugen Nears Critical Data Readout for Key Eye Disease Therapy - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Shares Down 4.6%Should You Sell? - MarketBeat
Ocugen Shares Surge Following Bullish Analyst Coverage - AD HOC NEWS
Ocugen (OCGN) Is Up 54.0% After Completing Phase 3 OCU400 Enrollment And Facing Going-Concern Warning - simplywall.st
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight - Yahoo Finance
Analyst Confidence Sparks Surge in Ocugen Shares - AD HOC NEWS
Ocugen Stock Jumps as Oppenheimer Initiates Outperform Rating - StocksToTrade
Ocugen’s Shares Leap 32% Post Oppenheimer’s Positive Coverage - timothysykes.com
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Stock Surges Amid Positive Analyst Coverage and Clinical Progress - StocksToTrade
Ocugen Stock Surges Amid Oppenheimer’s Bullish Forecast - timothysykes.com
Ocugen, Inc. (NASDAQ: OCGN) Q4 2025 earnings call transcript - MSN
Ocugen Stock Soars Following Strategic Developments in Gene Therapy Trials - timothysykes.com
Ocugen (NASDAQ:OCGN) Shares Gap UpStill a Buy? - MarketBeat
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline - AOL.com
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - AOL.com
Ocugen, Inc. (OCGN) Stock Forecast 2027, 2031 & 7-Year Price Prediction | Meyka AI - Meyka
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story - Yahoo Finance
Ocugen (OCGN) Valuation Update As Phase 3 OCU400 Enrollment Completes And Going Concern Risks Persist - simplywall.st
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - AOL.com
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - AOL.com
Ocugen (OCGN) Surges to 52-Week High on Oppenheimer's Outperform Rating - GuruFocus
Investors Buy Large Volume of Ocugen Call Options (NASDAQ:OCGN) - MarketBeat
Ocugen stock wins new Outperform at Oppenheimer (OCGN:NASDAQ) - Seeking Alpha
Ocugen (NASDAQ:OCGN) Hits New 12-Month HighWhat's Next? - MarketBeat
Ocugen (NASDAQ:OCGN) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
OCGN: Oppenheimer Initiates Coverage with Outperform Rating | OC - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for Ocugen - MarketBeat
Oppenheimer Initiates Ocugen at Outperform With $10 Price Target - marketscreener.com
Oppenheimer initiates Ocugen stock rating at Outperform on gene therapy potential - Investing.com
Ocugen price target raised to $22 from $15 at Lucid Capital - TipRanks
Oppenheimer initiates coverage of Ocugen (OCGN) with outperform recommendation - MSN
Ocugen's Clinical Ambition Meets Market Skepticism - AD HOC NEWS
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):